Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.4.2591

Clinical Comparison between Paclitaxel Liposome (Lipusu®) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer  

Xu, Xu (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Wang, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Xu, Huan-Qin (Deaprtment of Internal Medicine, GaoGang People Hospital)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Qian, Ya-Dong (Deaprtment of Internal Medicine, GaoGang People Hospital)
Xiang, Jin (Department of Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.4, 2013 , pp. 2591-2594 More about this Journal
Abstract
Aim: To compare the efficacy and safety of paclitaxel liposome (Lipusu$^{(R)}$) with paclitaxel in combination with tegafur and oxaliplatin in treating patients with advanced gastric cancer. Materials and Methods: Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups. Patients in group A received paclitaxel liposomes at a dose of 135 $mg/m^2$ on day 1 of each cycle, and patients in group B were given paclitaxel at the same dose with the same timing. All patients received tegafur at a dose of 500 $mg/m^2$ on days 1-5, and oxaliplatin at a dose of 80-100 $mg/m^2$ on day 1 for 2 cycles (each cycle was 21 d in total). Results: Fifty-eight patients could be evaluated for efficacy. The overall response rate was 47% in group A (14/30), and 46% in group B (13/28). Disease control rate was 73% in group A (22/30), and 71% in group B (20/28) (P>0.05). No significant differences were detected in hematologic and neurologic toxicities between the two groups (P>0.05). However, nausea, vomiting and hypersensitive reactions were significantly lower in group A than in group B (P<0.05). Conclusion: Paclitaxel liposomes are as effective as paclitaxel when combined with tegafur and oxaliplation in treating patients with advanced gastric cancer, but adverse reactions with paclitaxel liposomes are less common.
Keywords
Paclitaxel liposomes; pactitaxel; grast cancer; combined chemotherapy; adverse reactions;
Citations & Related Records
Times Cited By KSCI : 9  (Citation Analysis)
연도 인용수 순위
1 Belotti D, Vergani V, Drudis T, et al (1996). Themicrotubuleaffecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res, 2, 1843-9.
2 Bookman MA, Kloth DD, Kover PE, et al (1997). Shortcourse intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol, 8, 611-4.   DOI   ScienceOn
3 Chen Q, Zhang Q, Liu J, et al (2003). Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non small-cell lung cancer. Chin J Oncol, 25, 190-2.
4 Drummond DC, Meyer O, Hong K, et al (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 51, 691-743.
5 Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI   ScienceOn
6 Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
7 Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.   DOI   ScienceOn
8 Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
9 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
10 Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
11 Kobayashi M, Tsuburaya A, Nagata N, et al (2006). A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer, 9,114-9.   DOI
12 Kong Fh, Dong Qf, Cao X (2007). Effect of paclitaxel combined with cisplatin in treatment of non small cell lung cancer. Pract J Cancer, 22, 513-4.
13 Kucukzeybek Y, Dirican A, Erten C, et al (2012). Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. Asian Pac J Cancer Prev, 13, 2771-4.   DOI   ScienceOn
14 Li CG, Huang XE, Li Y (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
15 Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
16 Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.   DOI   ScienceOn
17 Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
18 Scialli AR, Waterhouse TB, Desesso JM, et al (1997). Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. Teratology, 56, 305-10.   DOI
19 Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14.   DOI   ScienceOn
20 Luo J, Wu FY, Li AW, et al (2012). Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study. Asian Pac J Cancer Prev, 13, 4703-6.   과학기술학회마을   DOI   ScienceOn
21 Sharma A, Straubinger RM (1994). Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res, 11, 889-96.   DOI
22 Sharma D, Chelvi TP, Kaur J, et al (1996). Novel taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated taxol for drug delivery in cancer therapy. Oncol Res, 8, 281-6.
23 Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.   DOI   ScienceOn
24 Szebeni J, Muggia FM, Alving CR (1998). Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst, 90, 300-6.   DOI   ScienceOn
25 Treat J, Damjanov N, Huang C, et al (2001). Liposomal encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology, 15, 44-8.
26 Van Zuylen L, Karlsson MO, Verweij J, et al (2001). Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol, 47, 309-18.   DOI   ScienceOn
27 Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro Polymorphism and Bladder Cancer Risk-Meta-analysis Evidence for a Link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.   DOI   ScienceOn
28 Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
29 Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
30 Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
31 Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
32 Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
33 Yang A, Li J, Xu H, et al (2006). A study on antitumor effect of liposome encapsulated paclitaxel in vivo and in vitro. Bull Chin Cancer, 15, 862-4.
34 Yao CY, Huang XE, Tang JH, et al (2010). Clinical observationson safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pac J Cancer Prev, 11, 553-5.
35 Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.   DOI   ScienceOn
36 Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
37 Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
38 Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.   DOI   ScienceOn